BLACKROCK CAPITAL ALLOC TR (BCAT)
US09260U1097
We assign a fundamental rating of 3 out of 10 to BCAT. BCAT was compared to 0 industry peers in the Unkown industry. The financial health of BCAT is average, but there are quite some concerns on its profitability. While showing a medium growth rate, BCAT is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
BCAT had positive earnings in the past year.
In the past year BCAT had a positive cash flow from operations.
1.2 Ratios
The last Return On Invested Capital (2.49%) for BCAT is above the 3 year average (2.16%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.1% | ||
| ROE | 7.9% | ||
| ROIC | 2.49% |
ROA(3y)-0.14%
ROA(5y)N/A
ROE(3y)-0.49%
ROE(5y)N/A
ROIC(3y)2.16%
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of BCAT has declined.
In the last couple of years the Operating Margin of BCAT has grown nicely.
BCAT's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 70.06% | ||
| PM (TTM) | 174.59% | ||
| GM | 72.04% |
OM growth 3Y22.71%
OM growth 5YN/A
PM growth 3Y-39.07%
PM growth 5YN/A
GM growth 3Y21.45%
GM growth 5YN/A
2. Health
2.1 Basic Checks
BCAT has less shares outstanding than it did 1 year ago.
BCAT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.76 indicates that BCAT is not in any danger for bankruptcy at the moment.
BCAT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.76 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
BCAT has a Current Ratio of 0.16. This is a bad value and indicates that BCAT is not financially healthy enough and could expect problems in meeting its short term obligations.
BCAT has a Quick Ratio of 0.16. This is a bad value and indicates that BCAT is not financially healthy enough and could expect problems in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.16 | ||
| Quick Ratio | 0.16 |
3. Growth
3.1 Past
BCAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 165.47%, which is quite impressive.
BCAT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.32% yearly.
BCAT shows a decrease in Revenue. In the last year, the revenue decreased by -3.47%.
BCAT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 91.73% yearly.
EPS 1Y (TTM)165.47%
EPS 3Y18.32%
EPS 5YN/A
EPS Q2Q%350.1%
Revenue 1Y (TTM)-3.47%
Revenue growth 3Y91.73%
Revenue growth 5YN/A
Sales Q2Q%-1.7%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.25 indicates a reasonable valuation of BCAT.
When comparing the Price/Earnings ratio of BCAT to the average of the S&P500 Index (30.84), we can say BCAT is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.25 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.83 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
BCAT has a Yearly Dividend Yield of 13.65%, which is a nice return.
Compared to an average S&P500 Dividend Yield of 2.21, BCAT pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 13.65% |
5.2 History
BCAT has been paying a dividend for over 5 years, so it has already some track record.
BCAT has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years3
5.3 Sustainability
DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
BLACKROCK CAPITAL ALLOC TR
NYSE:BCAT (10/29/2024, 8:04:00 PM)
15.75
-0.07 (-0.44%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.69B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 13.65% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.25 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.1% | ||
| ROE | 7.9% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 70.06% | ||
| PM (TTM) | 174.59% | ||
| GM | 72.04% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.16 | ||
| Quick Ratio | 0.16 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)165.47%
EPS 3Y18.32%
EPS 5Y
EPS Q2Q%
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-3.47%
Revenue growth 3Y91.73%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y